Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB)
Abstract
INTRODUCTION:
We report the results of AIR-BX 1 and AIR-BX2, two randomized, double-blind, placebo-controlled international trials of AZLI in NCFB with 266 and 273 randomized subjects respectively. The primary endpoint was change in respiratory symptoms using a new, disease-specific health-related quality of life tool, Quality of Life-Bronchiectasis (QOL-B), following one course of therapy (ΔQOLB Day 28). Secondary endpoints were change in (ΔQOLB Day 84) after a second course of therapy and time to first protocol-defined exacerbation (PDE).
METHODS:
Subjects received 75 mg of AZLI TID or placebo via an eFlow nebulizer for two 28-day on/off cycles for a total of 112 days of observation. Inclusion criteria included confirmation of bronchiectasis by high resolution CT, presence of a target gram negative organism in sputum culture at screening and an FEV1 of ≥20% predicted.
RESULTS:
AIR-BX1 did not meet statistical significance for the primary endpoint of ΔQOLB at Day 28 (p=0.68) while AIR-BX2 did (p=0.011), although the magnitude of change relative to placebo was less than the minimal importance difference, calculated by anchor and distribution-based methods (7.8-9.3 points). Both studies failed to achieve a significant ΔQOLB at Day 84 and time to first PDE. AZLI treatment decreased bacterial burden in both studies. AEs and SAEs were more frequent in AZLI versus placebo arms in both studies, with a larger difference seen in AIR-BX1.
CONCLUSIONS:
AZLI did not provide significant…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 273 participants or records.
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.